A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Explore the Immunogenicity and Efficacy of ID93+GLA-SE Vaccine in BCG-Vaccinated Healthy Healthcare Workers
Latest Information Update: 15 May 2023
At a glance
- Drugs ID 93 (Primary)
- Indications Tuberculosis
- Focus Adverse reactions
- Sponsors Quratis
Most Recent Events
- 11 May 2023 Status changed from active, no longer recruiting to completed according to result published in the Infectious Diseases and Therapy
- 11 May 2023 Results assessing safety and Immunogenicity of the ID93 + GLA-SE Tuberculosis Vaccine in BCG-Vaccinated Healthy Adults published in the Infectious Diseases and Therapy
- 29 May 2019 Status changed from recruiting to active, no longer recruiting.